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Background: We previously reported that Asian ethnicity was a
favorable prognostic factor for overall survival (OS) in non-small
cell lung cancer (NSCLC). In this study, we performed a combined
data analysis from a Japanese Cancer Registry and a regional
California Cancer Registry to further validate this observation.
Methods: Retrospective population-based analysis of Japanese and
Caucasian patients with NSCLC with known smoking status from
the Japanese National Hospital Organization Study Group for Lung
Cancer and a Southern California Regional Cancer Registry between
1991 and 2001.
Results: A total of 15,185 Japanese and 13,332 US Caucasian patients
were analyzed. Median age of Japanese patients was 68 years compared
with 69 years for Caucasian patients (p 0.0001). A total of 29.3% of
Japanese compared with 7.3% Caucasian patients were never-smokers.
Never-smoking status conferred significant improved OS for Japanese
(p 0.0001) and a trend for improved OS for Caucasian patients (p
0.1282). Univariate analysis revealed Japanese patients with stage III
(versus Caucasian; hazard ratio [HR] 0.830, 95% confidence interval
[CI]: 0.789–0.873, p  0.0001) and IV disease (versus Caucasian;
HR  0.955, 95% CI: 0.915–0.997, p  0.0369) had improved OS
compared with Caucasian patients. Multivariate analysis revealed Jap-
anese ethnicity (versus Caucasian; HR 0.937, 95% CI: 0.898–0.978,
p  0.0028) and never-smoker status (versus ever-smoker; HR 
0.947, 95% CI: 0.909–0.987, p 0.0104) to be independent favorable
factors for OS in addition to younger age, female gender, early stage,
and treatment received (surgery, radiation, and chemotherapy).
Conclusions: Japanese ethnicity when compared with Caucasian
ethnicity and never-smoker status are independent favorable prog-
nostic factors for OS in NSCLC.
Key Words: Japanese ethnicity, Caucasian ethnicity, Prognostic
factor, Cancer registry, Never-smoker, Non-small cell lung cancer.
(J Thorac Oncol. 2010;5: 1001–1010)
Lung cancer is the leading cancer cause of mortality glo-bally.1 In addition, cancer mortality from lung cancer
patients who are never-smokers constituted the seventh lead-
ing cause of death globally.1 Never-smokers with non-small
cell lung cancer (NSCLC) are found disproportionately in
Asian female patients with adenocarcinoma. Never-smokers
tend to harbor activating mutations in the epidermal growth
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factor receptor (EGFR) tyrosine kinase domain and tend to
have better survival than ever-smokers.2,3 A recent random-
ized trial of first-line chemotherapy showed that Asian pa-
tients had about 10 months greater overall survival (OS)
compared with Caucasian patients regardless of treatment
received.4 Another randomized trial conducted solely in Asia
that enrolled never-smokers or light smokers comparing a
oral EGFR tyrosine kinase inhibitor (TKI) with carboplatin/
paclitaxel chemotherapy indicated that Asian patients regard-
less of mutational status of the EGFR had OS survival
estimate that were higher than OS for Caucasian patients
from randomized trials.5 Thus, the analysis on the prognostic
significance of Asian ethnicity in determining the outcome of
NSCLC may be confounded by smoking status.
One of the ongoing projects of the International Associa-
tion for the Study of Lung Cancer International Staging Com-
mittee is to create a prospective database for future staging
refinements and to analyze prognostic factors according to tumor
and patient characteristics.6 Potential confounding prognostic
factors such as ethnicity, gender, and smoking status7 need to be
independently verified so that future global trials for lung cancer
treatment can be stratified for these factors.
Using the Southern California regional California Can-
cer Registry (CCR), we have previously reported that Asian
ethnicity is an independent favorable prognostic factor for OS
in NSCLC even after factoring in smoking status.8 However,
given the relative small number of Asian patients (6.5%) in
the study, we extended our observation to populations with
large number of Asian and Caucasian patients. The National
Hospital Study Group for Lung Cancer (NHSGLC) in Japan
has collected clinicopathologic and survival outcomes data on
approximately 30,000 Japanese patients with lung cancer.9,10
We combined both NHSGLC and the same regional CCR
data and performed epidemiologic analysis of Japanese and
Caucasian patients with NSCLC to further investigate whether
Asian ethnicity is an independent favorable prognostic factor for
OS in NSCLC after accounting for smoking status and other
prognostic factors. We limited our analysis up to the end of
2001, which is before the approval of gefitinib in Japan because
gefitinib has been shown to improve survival outcomes of
patients with NSCLC with EGFR activating mutations in Ja-
pan11 and may confound our analysis because of the higher
proportion of EGFR mutation-positive patients among Japanese
compared with Caucasians.3
PATIENTS AND METHODS
This was a retrospective study involving analysis of
data from the Cancer Surveillance Programs of Orange,
Imperial, and San Diego counties (CSPOC/SANDIOCC da-
tabases) in the state of California, USA, and the NHSGLC in
Japan. The NHSGLC was established in 1972 and funded by
the Japanese government at the same time that a lung cancer
registry was also established. NHSGLC consists of 42 hos-
pitals, and information from more than 2000 patients with
lung cancer has been collected each year, representing 3 to
4% of all Japanese patients with lung cancer.9,10
Patients with NSCLC diagnosed between 1991 and 2001
with complete follow-up data through January 20, 2007, were
included in the study. Only Caucasian patients from the regional
CCR were included in the study. Tumor site and histology were
abstracted as previously described.12 Bronchioloalveolar carci-
noma was classified as adenocarcinoma. The histology category
of mixed/carcinoma not otherwise specified/other was obtained
by examining histologic codes that did not further classify
NSCLC into adenocarcinoma, squamous cell, or large cell
carcinoma. American Joint Committee on Cancer (AJCC)
stages were available from the NHSGLC and were deter-
mined from programming according to the 6th edition AJCC
staging system using available clinical and pathologic tumor,
node, metastasis data from the CCR.
We analyzed differences and similarities between Japan
and Caucasian ethnicities according to eight variables com-
mon to both registries: age, gender, histology, AJCC stage,
period of diagnosis, surgery, radiation, and chemotherapy.
World Health Organization performance status, amount of
smoking (pack-years), response to chemotherapy, presenting
symptoms, and reasons for diagnosis were unique to the
NHSGLC database. Socioeconomic status and marital status
were unique to the California database. These variables were
not analyzed.
Smoking status in California was abstracted by examining
individual patient text file using a text-mining program as
previously described.8,12 Patients with any documented history
of smoking were classified as “ever-smokers.” Patients with
documentation of no smoking history were classified as “never-
smokers.” In Japan “never-smoker” was defined as a patient who
smoked fewer than 100 cigarettes lifetime and an “ever-smoker”
was defined as one who smoked 100 cigarettes or more in their
lifetime.
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for patients with NSCLC using Pear-
son’s 2 statistic or Fisher’s exact test for nominal variables
and Student’s t test for continuous variables. Comparison of
nonparametric values across the two groups was done using
the Wilcoxon rank sum test. Univariate survival rate analyses
were estimated using the Kaplan and Meier method, with
comparisons made between groups by the log-rank test. Cox
proportional hazards modeling using time since diagnosis
was performed. All statistical analyses were conducted using
SAS 9.2 statistical software (SAS Institute, Inc., Cary, NC).
Statistical significance was assumed for a two-tailed p value
less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (IRB #2007-
6078) and by the institutional review boards of the National
Hospital Organization Kinki-Chuo Chest Medical Center and
the NHSGLC.
RESULTS
Patient Characteristics
A total of 15,185 Japanese and 13,332 US Caucasian
patients were analyzed. The median age of the whole study
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population was 69 years (95% confidence interval [CI]:
49–83). The median follow-up time was 10 months (95% CI:
1–87). The median age of Japanese patients was 68 years
compared with 69 years for Caucasian (p  0.0001). A total
of 29.3% of Japanese compared with 7.3% Caucasian patients
were never-smokers (p  0.0001). There were more female
Caucasian patients with NSCLC (46.0%) than Japanese fe-
male patients with NSCLC (27.7%) (p  0.0001). A total of
14.6% of the Caucasian compared with 9.7% of the Japanese
patients were the very elderly (80 years). Adenocarcinoma
was the most common histology among Japanese (55.8%)
and Caucasian (45.3%) patients (Table 1).
Patient Characteristics by Gender According to
Smoking Status
Most of Japanese female patients with NSCLC were
never-smokers (76.3%) compared with only 9.9% of Cauca-
sian female patients with NSCLC (p  0.0001). The propor-
TABLE 1. Clinicopathologic Characteristics of Japanese and Caucasian Patients with NSCLC
(N  28,517)
Japan US p Total
N 15,185 13,332 28,517
Median age of diagnosis (95% CI) 68 (48–82) 69 (50–84) 0.0001a 69 (49–83)
Median follow-up time (mo) (95% CI) 10 (1–69) 9 (0–106) 0.0001a 10 (1–87)
Smoking status
Ever-smoker 10,731 (70.7) 12,355 (92.7) 23,086 (81.0)
Never-smoker 4454 (29.3) 977 (7.3) 0.0001 5431 (19.0)
Period of diagnosis
1991–1996 8228 (54.2) 7451 (55.9) 15,679 (55.0)
1997–2001 6957 (45.8) 5881 (44.1) 0.0039 12,838 (450)
Gender
Male 10,982 (72.3) 7197 (54.0) 18,179 (63.8)
Female 4203 (27.7) 6135 (46.0) 0.0001 10,338 (36.3)
Age category (yr)
0–39 180 (1.2) 78 (0.6) 258 (0.9)
40–49 823 (5.4) 583 (4.4) 1406 (4.9)
50–59 2366 (15.6) 1956 (14.7) 4322 (15.2)
60–69 5173 (34.1) 4094 (30.7) 9267 (32.5)
70–79 5171 (34.1) 4671 (35.0) 9842 (34.5)
80 1472 (9.7) 1950 (14.6) 0.0001 3422 (12.0)
Histology
Adenocarcinoma 8477 (55.8) 6036 (45.3) 14,513 (50.9)
Squamous cell carcinoma 5386 (35.5) 3215 (24.1) 8601 (30.2)
Large cell carcinoma 752 (5.0) 1010 (7.6) 1762 (6.2)
Undifferentiated/mixed/NOS 570 (3.8) 3071 (23.0) 0.0001 3641 (12.8)
AJCC stage
I 4779 (31.4) 2410 (18.1) 7189 (25.2)
II 918 (6.1) 746 (5.6) 1664 (5.8)
III 5514 (36.3) 2522 (18.9) 8036 (28.2)
IV 3821 (25.2) 5682 (42.6) 9503 (33.3)
Unknown 153 (1.0) 1972 (14.8) 0.0001 2125 (7.5)
Surgery
Yes 7254 (47.8) 3941 (29.6) 11,195 (39.3)
No 7849 (51.7) 9369 (70.3) 17,218 (60.4)
Unknown 82 (0.5) 22 (0.2) 0.0001 104 (0.4)
Radiation
Yes 4488 (29.6) 5910 (44.3) 10,398 (36.5)
No 10,585 (69.7) 7418 (55.6) 18,003 (63.1)
Unknown 112 (0.7) 4 (0.03) 0.0001 116 (0.4)
Chemotherapy
Yes 6792 (44.7) 3542 (26.6) 10,334 (36.2)
No 8346 (55.0) 9749 (73.1) 18,095 (63.5)
Unknown 47 (0.3) 41 (0.3) 0.0001 47 (0.3)
a Wilcoxon rank sum test.
NSCLC, non-small cell lung cancer; CI, confidence interval; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer.
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tion of Japanese male patients with NSCLC who were never-
smokers was low (11.4%), but it is still more than double the
proportion of Caucasian male patients with NSCLC who
were never-smokers (5.1%, p  0.0001) (Table 2).
Patient Characteristics by Smoking Status
According to Gender
The comparisons of the clinicopathologic characteris-
tics of Japanese and Caucasian patients by smoking status and
gender are listed in Table 3. Females made up of 9.3% of
Japanese ever-smokers but made up of 72.0% of Japanese
never-smokers. A similar but less dramatic reversal of gender
composition was also observed from Caucasian ever-smokers
(44.7% female) to never-smokers (62.6% female). The me-
dian age of Caucasian never-smokers was significantly older
than ever-smokers overall (74 versus 69 years, p  0.0001),
among males (71 versus 69 years, p  0.0015), and among
females (75 versus 70 years, p  0.0001). On the other hand,
Japanese never-smokers were significantly younger than ev-
er-smokers overall (67 versus 68 years, p  0.0001) and
among females (66 versus 69 years, p  0.0004). As such,
33.4% of Caucasian female never-smokers were 80 years.
The proportion of adenocarcinoma increased among never-
smokers especially in Japanese culminating in adenocarci-
noma making up to 88.4% of the histology of Japanese
female never-smokers. Of note, squamous cell carcinoma
(45.1%) edged out adenocarcinoma (45.0%) as the most
common histology among Japanese ever-smokers whereas
adenocarcinoma (44.1%) was the most common histology
among Caucasian ever-smokers (Table 3).
Univariate Survival Analysis
The OS of individual clinicopathologic characteristic
within Japanese and Caucasian patients are listed in Table 4.
Female patients, early-stage patients, and patients with ade-
nocarcinoma all had significantly improved OS within both
Japanese and Caucasian patients. Pairwise comparisons of
individual clinicopathologic variable are listed in Table 5.
With the exception of stage I and II patients and unknown
stage, surgery, or chemotherapy received, Japanese patients
had improved OS compared with Caucasian patients by
unadjusted hazard ratio (HR) analysis.
Smoking Status
Japanese never-smokers had significantly improved OS
when compared with Japanese ever-smokers (p  0.0001;
Table 3) (Figure 1A), whereas there was no statistically
significant difference in OS between Caucasian never-smok-
ers and ever-smokers (p  0.1481; Table 4) (Figure 1B).
Gender
Females had significantly improved OS when com-
pared with males among both Japanese (p  0.0001) and
Caucasian (p 0.0001) patients (Table 4). Furthermore, both
Japanese male and female patients had significantly improved
survival compared with Caucasian male and female patients,
respectively (Table 5).
Ethnicity by Stage
Among stage I and II patients, there were no significant
survival differences between Japanese and Caucasian pa-
tients. Among stage III and IV patients, there were statisti-
cally significant improved OS for Japanese patients when
compared with Caucasian patients (Table 5).
Multivariate Survival Analysis
We analyzed the independence of the nine variables as
prognostic factors for OS in NSCLC, especially ethnicity and
smoking status (Table 6). By Cox proportional hazards anal-
ysis, Japanese ethnicity (versus Caucasian; HR 0.955, 95%
CI: 0.917–0.995, p  0.0268) and never-smoker status (ver-
sus ever-smoker; HR  0.945, 95% CI: 0.906–0.985, p 
0.0076) were favorable prognostic factors for OS (Table 6).
Other independent favorable prognostic factors include younger
age, early tumor stage, most recent period of diagnosis, and
treatment (surgery, radiation, and chemotherapy). There was a
significant interaction between Japanese ethnicity and chemo-
therapy use (p  0.0001) and this was adjusted for in the Cox
multivariate analysis. Among stage III/IV patients, the HR for
OS for Japanese patients compared with Caucasian patients was
0.907 (95% CI: 0.861–0.956; p  0.0003).
DISCUSSION
The introduction of oral EGFR TKIs and the subse-
quent discovery of activating EGFR mutations has led to the
appreciation of ethnic differences in NSCLC especially be-
tween Asians and Caucasians.2,3 The higher proportion of
never-smokers and EGFR mutations among Asians and the
better response to oral EGFR TKIs among Asians further
demonstrate the prognostic importance of ethnicity in
NSCLC. Several lines of evidence have shown that when
compared in a uniform fashion, Asians have improved OS in
NSCLC. The first is large-scale randomized trials conducted
globally in which patients from different parts of the world
were enrolled and allow for analysis of survival difference by
ethnicity.4,13–15 Second is the “common arm” approach in
which identical eligibility criteria and treatment protocols
were utilized in clinical trials in different countries with
prespecified combined analysis of patients enrolled in the
“common arm.”16,17 Third is to perform retrospective analysis
of large cancer registry in an ethnically diverse population8 or
TABLE 2. Comparison of Japanese and Caucasian Patients
by Smoking Status According to Gender
Japanese Caucasian p
Male
N 10,982 7197
Smoking status
Never-smoker (%) 11.4 5.1
Ever-smoker (%) 88.7 94.9 0.0001
Female
N 4203 6135
Smoking status
Never-smoker (%) 76.3 9.9
Ever-smoker (%) 23.7 90.1 0.0001
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perform combined analysis of large cancer registries using
common clinicopathologic characteristics as in this report.
In this report, we successfully combined and retrospec-
tively analyzed two large-scale population-based cancer reg-
istries using eight identical tumor-related and patient-related
parameters. Therefore, we were also able to compare the
epidemiologic characteristics of Japan and US Caucasian
patients with NSCLC. First, both Japanese and US Caucasian
patients were elderly (69 versus 70 years; p  0.0001).
Furthermore, a relatively high proportion of patients were the
very elderly (80 years) among both Japanese (9.7%) and
Caucasian (14.6%) patients. This reflects an ongoing chal-
lenge in NSCLC treatment in which the latency period
development of NSCLC could last up to 35 years after
cessation of tobacco use. Without any proven effective
screening methods, a significant proportion of NSCLC will
be diagnosed among the very elderly who are less amenable
to optimal treatment because of a combination of societal and
patient factors. Second, adenocarcinoma was the most com-
mon NSCLC histology among both Japan and US patients
while large cell carcinoma was relatively rare comprising
only 5.0% of Japan and 7.9% of US Caucasian patients with
TABLE 4. Univariate Analysis of Survival of Japanese and Caucasian Patients
Japan US
N
Median
OS (mo)
2-yr Survival
Estimates (%) p N
Median
OS (mo)
2-yr Survival
Estimate (%) p
Smoking status
Ever-smoker 10,731 13 32.9 12,355 9 26.7
Never-smoker 4454 20 44.5 0.0001 977 10 28.9 0.1282
Gender
Male 10,982 13 33.0 7197 7 24.0
Female 4203 21 45.1 0.0001 6135 10 30.3 0.0001
Age category
0–39 180 15 32.7 78 8 24.4
40–49 823 17 39.7 583 11 29.4
50–59 2366 17 41.3 1956 10 31.3
60–69 5173 17 39.8 4094 10 30.4
70–79 5171 14 34.3 4671 8 25.5
80 1472 9 19.8 0.0001 1950 5 17.8 0.0001
Period of diagnosis
1991–1996 8228 15 37.1 7451 8 26.1
1997–2001 6957 15 34.1 0.0001 5881 9 27.8 0.0312
Histology
Adenocarcinoma 8477 17 39.3 6036 11 32.6
Squamous cell carcinoma 5836 14 34.0 3215 11 29.2
Large cell carcinoma 752 8 21.7 1010 6 20.0
Undifferentiated 570 13 32.5 0.0001 3071 5 15.5 0.0001
AJCC stage
I 4779 53 74.1 2410 55 68.5
II 918 24 49.4 746 23 48.1
III 5514 12 25.1 2522 9 20.3
IV 3821 5 6.5 5682 4 9.1
Unknown 153 8 21.7 0.0001 1972 10 27.6 0.0001
Surgery
Yes 7254 40 64.6 3941 45 64.0
No 7849 7 11.2 9369 5 11.3
Unknown 82 8 20.7 0.0001 22 9 13.6 0.0001
Radiation
Yes 4488 10 19.9 5910 8 18.7
No 10,585 19 43.8 7418 9 33.5
Unknown 112 18 40.9 0.0001 4 0 0.0 0.0001
Chemotherapy
Yes 6792 13 28.9 3542 10 21.3
No 8346 19 43.4 9749 8 28.9
Unknown 47 14 33.6 0.0001 41 9 27.6 0.0014
OS, overall survival; AJCC, American Joint Committee on Cancer.
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NSCLC. Of note, squamous cell carcinoma edged out ade-
nocarcinoma as the most common histology among ever-
smokers in Japan whereas adenocarcinoma was the most
among Caucasian ever-smokers and never-smokers. This
may reflect the differences in the tobacco exposure among
Japanese and Caucasian ever-smokers. The smoking preva-
lence in US male population has steadily declined, whereas in
Asia, the prevalence has remained the same. Squamous cell
carcinoma is the NSCLC histology most related to tobacco18
while adenocarcinoma is commonly found in former smok-
ers.19 One of the limitations of this study is the lack of amount
of tobacco exposure from the CCR. Third, Japanese NSCLC
patients had a significantly higher proportion of never-smok-
ers as compared with Caucasian NSCLC patients. The media
age of Japanese never-smokers were significantly younger
than ever-smokers (67 versus 68 years; p  0.0001) whereas
the median age of Caucasian never-smokers were signifi-
cantly older than ever-smokers (74 versus 69 years, p 
0.0001). It has been consistently shown that Caucasian never-
smokers were significantly older than ever-smokers.8,20 The
difference in median age of diagnosis may signify different
etiologies of lung cancer among Japanese and Caucasian
TABLE 5. Comparison of Survival Between Japanese and Caucasian Patients by Individual
Clinicopathologic Category
US Japan
Unadjusted HR
(95% CI) p
Median OS (mo)
(95% CI)
Median OS (mo)
(95% CI)
Overall 9 (8–9) 15 (14–15) 0.760 (0.740–0.780) 0.0001
Smoking status
Ever-smoker 9 (8–9) 13 (13–14) 0.815 (0.792–0.840) 0.0001
Never-smoker 10 (9–12) 20 (19–21) 0.678 (0.628–0.733) 0.0001
Gender
Male 7 (7–8) 13 (13–14) 0.760 (0.735–0.785) 0.0001
Female 10 (10–11) 21 (21–22) 0.664 (0.633–0.697) 0.0001
Age category (yr)
0–39 8 (6–11) 15 (11–18) 0.723 (0.540–0.969) 0.0297
40–49 11 (9–12) 17 (15–19) 0.747 (0.660–0.846) 0.0001
50–59 10 (10–11) 17 (16–19) 0.762 (0.709–0.818) 0.0001
60–69 10 (9–11) 17 (16–18) 0.791 (0.754–0.829) 0.0001
70–79 8 (8–9) 14 (13–15) 0.779 (0.744–0.815) 0.0001
80 5 (4–5) 9 (8–10) 0.795 (0.738–0.857) 0.0001
Period of diagnosis
1991–1996 8 (8–9) 15 (14–15) 0.721 (0.696–0.746) 0.0001
1997–2001 9 (8–9) 15 (15–16) 0.849 (0.813–0.886) 0.0001
Histology
Adenocarcinoma 11 (10–11) 17 (16–18) 0.829 (0.798–0.862) 0.0001
Squamous cell carcinoma 11 (10–12) 14 (13–15) 0.873 (0.831–0.917) 0.0001
Large cell carcinoma 6 (5–6) 8 (7–9) 0.889 (0.802–0.986) 0.0265
Undifferentiated 5 (5–6) 13 (11–15) 0.599 (0.539–0.666) 0.0001
AJCC stage
I 55 (50–59) 53 (49–56) 0.959 (0.894–1.029) 0.2416
II 23 (20–26) 24 (21–26) 0.985 (0.874–1.110) 0.8059
III 9 (8–9) 12 (11–12) 0.830 (0.789–0.873) 0.0001
IV 4 (2–11) 5 (5–6) 0.955 (0.915–0.997) 0.0369
Unknown 10 (9–11) 8 (7–10) 1.170 (0.971–1.411) 0.0991
Surgery
Yes 45 (42–48) 40 (38–41) 1.074 (1.019–1.131) 0.0076
No 5 (2–12) 7 (7–8) 0.874 (0.847–0.902) 0.0001
Unknown 9 (1–17) 8 (6–11) 0.810 (0.497–1.321) 0.3981
Radiation
Yes 8 (4–18) 10 (10–11) 0.910 (0.873–0.949) 0.0001
No 9 (9–10) 19 (18–20) 0.748 (0.722–0.775) 0.0001
Chemotherapy
Yes 10 (9–10) 13 (12–13) 0.807 (0.773–0.843) 0.0001
No 8 (7–8) 19 (18–19) 0.688 (0.664–0.713) 0.0001
Unknown 9 (3–16) 14 (8–24) 0.792 (0.488–1.286) 0.3460
HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer.
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never-smokers. Potential etiologies of lung cancer in never-
smokers have been reviewed extensively.21 A significant
higher proportion of Japanese patients were diagnosed with
early stage (stages I and II) and is likely due to the fact that
NHSGLC had more participating surgeons than medical on-
cologists with increased referral pattern for surgical interven-
tion for early-stage NSCLC and inclusion of more early-stage
patients in the NHSGLC database. It is also noteworthy that
Japanese female patients had median OS of 21 months, which
is 8 months better than Japanese male patients and 11 months
better than Caucasian female patients. This is likely driven in
part to the high proportion of Japanese females with stage I
disease. The proportion of Japanese female never-smokers
with stage I disease (46.2%) was higher than Japanese male
never-smokers (35.9%); similarly, the proportion of Japanese
ever-smokers with stage I disease (29.6%) was also higher
than Japanese ever-smokers (26.2%). Corollary, the propor-
tion of Japanese females with stage I disease was higher than
Caucasian female patients regardless of smoking status espe-
cially never-smokers (46.2% versus 18.9%). The lack of
significant difference by univariate analysis in OS between
stage I Japanese and Caucasian patients was likely due to the
long survival of both group of patients, and the two respective
survival curves crossed at around 60 months of follow-up.
The lack of significant difference by univariate analysis in OS
between stage II Japanese and Caucasian patients was likely
due to both the prolonged survival and the limited number of
patients with stage II disease as opposed to other stages.
By multivariate analysis, we identified Japanese ethnic-
ity compared with Caucasian ethnicity, never-smoker status,
and female gender to be independent favorable prognostic
factors. Our findings are in agreement with published litera-
ture. Several phase 3 clinical trials in NSCLC have indicated
that Asians had numerically superior survival compared with
Caucasian patients.4,13–15 Indeed, smoking status and Asian
ethnicity is an independent variable in a prognostic model for
oral EGFR TKI, erlotinib.14 Using a “common arm” ap-
proach, Gandara et al.16 also reported a 3- to 5-month im-
TABLE 6. Cox Model for Overall Survival
Hazard
Ratio
95% Confidence
Interval p
Smoking status
Ever-smoker 1.000
Never-smoker 0.947 0.909–0.987 0.0104
Ethnicity
Caucasian 1.000
Japanese 0.937 0.898–0.978 0.0028
Gender
Male 1.000
Female 0.834 0.809–0.860 0.0001
AJCC stagea
I 1.000
II 1.696 1.585–1.815 0.0001
III 2.260 2.155–2.370 0.0001
IV 3.367 3.208–3.533 0.0001
Age 1.010 1.008–1.011 0.0001
Histology
Adenocarcinoma 1.000
Squamous cell carcinoma 0.975 0.939–1.013 0.2003
Large cell carcinoma 0.987 0.949–1.026 0.4962
NOS/mixed/other 1.266 1.143–1.402 0.0001
Period of diagnosis
1991–1996 1.000
1997–2001 0.992 0.965–1.019 0.5578
Surgerya
No 1.000
Yes 0.330 0.317–0.343 0.0001
Radiationa
No 1.000
Yes 0.857 0.831–0.883 0.0001
Chemotherapy
No 1.000
Yes 0.654 0.627–0.683 0.0001
a Unknown included in the analysis but not shown.
FIGURE 1. A, Kaplan-Meier survival curves of Japanese patients with NSCLC according to smoking status. B, Kaplan-Meier
survival curves of US Caucasian patients with NSCLC according to smoking status.
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provement in OS of Japanese patients compared to US
patients who received carboplatin/paclitaxel as first-line treat-
ment of NSCLC (12 or 14 months versus 9 months; p 
0.0006). The use of oral EGFR TKIs has been proposed as
part of the reason for the observed improved OS of Japanese
patients21 whereas others have suggested that there may be
differences between tumor in Japanese and non-Japanese
patients with NSCLC.17 Finally, this study helped extend our
observation that Asian ethnicity is an independent prognostic
factor in OS in NSCLC.8
There are several advantages of this study. First, large
numbers (approximately 30,000) of patients with known
smoking status were analyzed. NHSGLC included 42 hospi-
tals, so it represents a large segment of patients with NSCLC
in Japan. Second, important clinical parameters including
age, gender, AJCC stage, histology, treatment were included
in the analysis. Third, we limited the study period to before
2002 to limit the contribution and treatment effect of EGFR
TKIs in the improved survival of Asian patients.11,13,22
There are several limitations in this study. Several inde-
pendent prognostic factors such as performance status6,7 and
tumor differentiation8 were not included in the analysis be-
cause tumor differentiation was not available in the NHSGLC
and performance status was not available in the CCR. In
addition, the NHSGLC is a hospital-based rather than a
population-based registry such that the patients included in
the study could be subjected to referral bias. Moreover, the
proportion of EGFR mutations and the frequency of use of
EGFR TKIs (gefitinib and erlotinib) could not be ascertained
from both databases. Furthermore, a very small portion of the
patients diagnosed around 2001 may have been treated with
EGFR TKIs, which could favorably affect the survival of
these patients. However, a study from Korea has indicated
that it is valid to use year 2001 as the divide between pre- and
post-EGFR TKIs eras.22 Finally, the amount of tobacco
exposure was not available in the CCR and thus not analyzed
in this study. The amount of environmental tobacco smoke or
other environmental exposure was not captured in both data-
bases, thus we could not account for any contribution of
environmental tobacco smoke to the development of NSCLC
among Japanese or Caucasian patients.
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